Serum γ-glutamyl Transferase Levels, Insulin Resistance and Liver Fibrosis in Patients with Chronic Liver Diseases

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Petta, Salvatore ^a   Macaluso, Fabio Salvatore ^a   Barcellona, Maria Rosa ^a   Cammà, Calogero ^a   Cabibi, Daniela ^a   Di Marco, Vito ^a   Craxì, Antonio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE;

ADULT; ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NONALCOHOLIC FATTY LIVER; PREDICTIVE VALUE; PREVALENCE; SEX DIFFERENCE;

ADULT; CHRONIC DISEASE; COHORT STUDIES; DEMOGRAPHY; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; INSULIN RESISTANCE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS;

HEPATITIS C VIRUS;

EID: 84870846181     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051165     Document Type: Article

References (35)

1. Herzer K, Sprinzl MF, Galle PR, (2007) Hepatitis viruses: Live and let die. Liver Int 27: 293-301.
2. Petta S, Muratore C, Craxì A, (2009) Non-alcoholic fatty liver disease pathogenesis: the present and the future. Dig Liver Dis 41: 615-25.
3. Petta S, Craxì A, (2010) Hepatocellular carcinoma and non-alcoholic fatty liver disease: from a clinical to a molecular association. Curr Pharm Des 16: 741-52.
4. Petta S, Amato M, Cabibi D, Cammà C, Di Marco V, et al. (2010) Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1. Hepatology 52: 1543-52.
5. Cammà C, Petta S, (2009) Insulin resistance in HCV mono-infected and in HIV/HCV co-infected patients: Looking to the future. J Hepatol 50: 648-51.
6. Petta S, Cammà C, Di Marco V, Alessi N, Cabibi D, et al. (2008) Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am J Gastroenterol 103: 1136-44.
7. Everhart JE, Lok AS, Kim HY, Morgan TR, Lindsay KL, et al. (2009) HALT-C Trial Group. Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology 137: 549-57.
8. Petta S, Cammà C, Di Marco V, Macaluso FS, Maida M, et al. (2011) Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. Liver Int 31: 507-15.
9. Cammà C, Bruno S, Di Marco V, Di Bona D, Rumi M, et al. (2006) Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology. 43: 64-71.
10. Park SH, Kim DJ, Lee HY, (2009) Insulin resistance is not associated with histologic severity in nondiabetic, noncirrhotic patients with chronic hepatitis B virus infection. Am J Gastroenterol 104: 1135-9.
11. Belfort R, Harrison SA, Brown K, Darland C, Finch J, et al. (2006) A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis. NEJM 355;22997-2307.
12. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, et al. (2010) Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis. NEJM 362: 1675-85.
13. Nemesanszky E, Lott JA, (1985) Gamma-glutamyltransferase and its isoenzymes: progress and problems. Clin Chem 31: 797-803.
14. Whitfield JB. Gamma glutamyl transferase, (2001) Crit Rev Clin Lab Sci. 38: 263-355.
15. Lee DS, Evans JC, Robins SJ, Wilson PW, Albano I, et al. (2007) Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 27: 127-133.
16. Lee DH, Jacobs DR Jr, Gross M, Kiefe CI, Roseman J, et al. (2003) Gammaglutamyltransferase is a predictor of incident diabetes and hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem 49: 1358-1366.
17. Kazemi-Shirazi L, Endler G, Winkler S, Schickbauer T, Wagner O, et al. (2007) Gamma glutamyltransferase and long-term survival: is it just the liver? Clin Chem 53: 940-946.
18. Jo SK, Lee WY, Rhee EJ, Won JC, Jung CH, et al. (2009) Serum gamma-glutamyl transferase activity predicts future development of metabolic syndrome defined by 2 different criteria. Clin Chim Acta 403: 234-40.
19. Leite NC, Villela-Nogueira CA, Pannain VL, Bottino AC, Rezende GF, et al. (2011) Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors. Liver Int 31: 700-6.
20. Dixon JB, Bhathal PS, O'Brien PE, (2006) Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement. Obes Surg 16: 1278-1286.
21. Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, et al. (2002) Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat 9: 128-33.
22. Seto WK, Lee CF, Lai CL, Ip PP, Fong DY, et al. (2011) A new model using routinely available clinical parameters to predict significant liver fibrosis in chronic hepatitis B. PLoS One. 6(8): e23077.
23. American Diabetes Association. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus (2000) American Diabetes Association: Clinical Practice Recommendations 2000 Committee Report. Diabetes Care 23: S4-19.
24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
25. Ikeda Y, Suehiro T, Nakamura T, Kumon Y, Hashimoto K, (2001) Clinical significance of the insulin resistance index as assessed by homeostasis model assessment. Endocr J 48: 81-86.
26. Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, et al. (2008) Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 134: 416-23.
27. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 411: 313-321.
28. Scheuer PJ, (1991) Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 13: 372-4.
29. SAS Technical Report (1992) SAS/STAT software: changes and enhancement, Release 6.07. Cary, NC: SAS Institute, Inc.
30. Haring R, Wallaschofski H, Nauck M, Dörr M, Baumeister SE, et al. (2009) Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. HEPATOLOGY 50: 1403-1411.
31. Calori G, Lattuada G, Ragogna F, Garancini MP, Crosignani P, et al. (2011) Fatty liver index (FLI) and mortality: The cremona study at the 15(th) year of follow up. HEPATOLOGY 54: 145-152.
32. Loomba R, Rao F, Zhang L, Khandrika S, Ziegler MG, et al. (2010) Genetic covariance between gamma-glutamyl transpeptidase and fatty liver risk factors: role of beta2-adrenergic receptor genetic variation in twins. Gastroenterology 139: 836-845.
33. Middelberg RP, Benyamin B, de Moor MH, Warrington NM, Gordon S, et al. (2011) Loci affecting gamma-glutamyl transferase in adults and adolescents show age × SNP interaction and cardiometabolic disease associations. Hum Mol Genet 21: 446-55.
34. Petta S, Grimaudo S, Cammà C, Cabibi D, Di Marco V, et al. (2011) IL28B and PNPLA3 Polymorphisms Affect Histological Liver Damage in Patients with Non-alcoholic Fatty Liver Disease. J Hep 2012 56: 1356-62.
35. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, et al. (2010) Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 51: 121-9.